Search

Objective: SertaSil is a novel product for the topical management of wound exudate. The purpose of this study was to evaluate the ability of SertaSil to promote wound healing in a pre-clinical wound model. Method: An aseptic wound was induced in rats by administering 1ml 10% calcium chloride solution into the subcutaneous layer under local anaesthesia. Following opening of the abscess, animals were divided into a control group (no treatment) and either SertaSil or Gentaxane, which were applied topically to the wound every 24 hours until a clean wound was achieved, that is, free from necrosis, pus and fibrinogenous thickenings. Results: Rats (n=15 per group) receiving SertaSil reached the clean wound stage in 3.0±0.4 days compared to 7.0±0.4 days for Gentaxane and 10.0±0.4 days for the control. Time to wound closure was 13.9±0.3 days for SertaSil, 18.7±0.6 days for Gentaxane, and 23.0±0.4 days for the control. The surface area of the wounds were measured at day 1 and day 13. At day 1, the wound surface areas (mm2) were similar in all three groups (157.4±8.9), but at day 13 the SertaSil group had significantly smaller wound areas (5.2±1.7) compared to the Gentaxane (38.0±1.5) and control groups (95.7±11.3). The study was conducted in young rats that are still growing and gaining weight. At day 19, only the rats receiving SertaSil exhibited a weight increase (271±5g) indicating good recovery, whereas rats receiving Gentaxane did not gain weight (249±5g) and rats in the control group lost weight (242±16 g). Conclusion: The study found that SertaSil reduced the time to reaching a clean wound by 60% compared to Gentaxane and promoted faster wound closure and better recovery. These findings suggest that SertaSil may be valuable for use in the treatment of wounds in patients. Declaration of interest: Dr. Bilyayeva, Dr. Neshta and Dr. Golub are inventors of SertaSil and Dr. Sams- Dodd is from Willingsford Ltd. [ABSTRACT FROM AUTHOR]

Background & Aims: Although proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms. Topical mesalamine, the standard treatment, is not always effective. We conducted a randomized phase 2 trial to determine the efficacy and safety of 2 doses of a budesonide suppository vs mesalamine suppositories vs combined budesonide and mesalamine suppositories for proctitis., Methods: We performed a prospective, double-blind, double-dummy, multicenter trial in 337 patients with active proctitis to compare the efficacies of 4 different suppository treatments. Patients were randomly assigned to groups given 2 mg budesonide suppositories (2 mg BUS; n = 89 patients), 4 mg BUS (n = 79), 1 g mesalamine suppositories (1 g MES; n = 81), or the combination of 2 mg BUS and 1 g MES (n = 88). The study was performed from November 2013 through July 2015 at 36 study sites in Europe and Russia. The primary end point was the time to resolution of clinical symptoms, defined as the first of 3 consecutive days with a score of 0 for rectal bleeding and stool frequency., Results: The mean time to resolution of symptoms in the 4 mg BUS (29.8 days) and combination of 2 mg BUS and 1 g MES (29.3 days) groups resembled that of the standard 1 g MES treatment (29.2 days), but was significantly longer in the 2 mg BUS group (35.5 days). Furthermore, proportions of patients with deep, clinical, and endoscopic remission, as well as mucosal healing, were similar among the 1 g MES, 4 mg BUS, and combination therapy groups, but significantly lower in the group that received 2 mg BUS. No safety signals were observed, and the patients' treatment acceptance was high (67%-85% of patients)., Conclusions: In a multicenter randomized trial, we found that the efficacy and safety of 4 mg BUS in treatment of active proctitis did not differ significantly from those of 1 g MES. Budesonide suppositories offer an alternative therapy to mesalamine for topical treatment of proctitis. Clinicaltrialsregister.eu no: 2012-003362-41., (Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.)

The work objective is the results of complex treatment improvement in patients with diabetic foot syndrome. The work is based on the results of complex treatment analysis data in 32 patients suffering diabetes mellitus, complicated by diabetic foot syndrome. There was proved the efficacy of application in complex of curative measures of the applicating serpent of a new generation Sertasyl, which had lowered the risk of performance of the lower extremities high amputation, trusting necessity of its wide clinical application in such patients.